3 results match your criteria: "Unit of Clinical of Experimental Onco-Hematology[Affiliation]"
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination.
Int J Infect Dis
April 2023
Center for Global Health, Istituto Superiore di Sanità, Rome, Italy; UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy. Electronic address:
Article Synopsis
- The study analyzed trends in chronic hepatitis B patients in Italy through a multicenter observational cohort (PITER) from 2019-2021, comparing it to an earlier cohort (MASTER) from 2012-2015.
- Key findings revealed that the PITER cohort had older patients and a higher percentage of females, with a significant decline in HBeAg prevalence compared to MASTER, while rates of anti-HD virus remained stable.
- The study concludes that while chronic hepatitis B infection is becoming better managed in Italy, HDV remains a concern, particularly among patients with cirrhosis and non-Italian migrants.
Chronic hepatitis C: a systemic disease.
Minerva Med
April 2021
Unit of Clinical of Experimental Onco-Hematology, IRCCS Centro di Riferimento Oncologico di Aviano (CRO), Aviano, Pordenone, Italy -
Hepatitis C virus-related cryoglobulinemic vasculitis.
Minerva Med
April 2021
Unit of Clinical of Experimental Onco-Hematology, IRCCS Centro di Riferimento Oncologico (CRO), Aviano, Pordenone, Italy.
Article Synopsis
- Hepatitis C virus (HCV) infection affects around 170 million globally and can lead to chronic infection in about 70% of cases, which may progress to serious liver conditions and other health issues, including extra-hepatic manifestations like mixed cryoglobulinemia (MC) and non-Hodgkin lymphomas (NHL).
- Cryoglobulinemic vasculitis (CV) can cause a range of symptoms from mild (like leg purpura and fatigue) to severe (including life-threatening complications like gastrointestinal vasculitis), and is linked to significant morbidity and mortality, often necessitating treatment post-antiviral therapy.
- New direct antiviral agents (DAAs) show high